Medical Innovation Exchange

With Nasdaq delisting threat, IMV drops 3rd of staff in refocus on lead oncology asset

https://www.fiercebiotech.com/biotech/nasdag-delisting-looming-imv-drops-third-staff-refocus-lead-oncology-asset

Leave a Comment

Your email address will not be published.

Leave the field below empty!